Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS

Key Points

• Xilio Therapeutics beat quarterly estimates: The company reported an adjusted loss of $0.33 per share, $0.26 better than analysts’ expected loss of $0.59, while revenue of $18.69 million exceeded the $12.72 million consensus.
• Shares fell 2.5% to $8.95 during Wednesday trading. Xilio remains unprofitable, with a negative net margin of 58.52% and a market capitalization of approximately $58.9 million.
• Analyst sentiment remains negative: Recent ratings downgrades left the company with a consensus “Sell” rating, despite institutional investors owning 54.29% of its shares.

Xilio Therapeutics (NASDAQ:XLO - Get Free Report) released its earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.26, FiscalAI reports. The firm had revenue of $18.69 million during the quarter, compared to analysts' expectations of $12.72 million. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 151.42%.

Xilio Therapeutics Trading Down 2.5%

Shares of NASDAQ:XLO traded down $0.23 during trading on Wednesday, hitting $8.95. 3,707 shares of the company's stock were exchanged, compared to its average volume of 40,686. The firm has a 50-day moving average price of $8.84 and a two-hundred day moving average price of $8.36. Xilio Therapeutics has a 1-year low of $6.47 and a 1-year high of $12.74. The firm has a market cap of $58.89 million, a P/E ratio of -2.52 and a beta of -0.14.

Analyst Upgrades and Downgrades

XLO has been the topic of a number of recent research reports. Weiss Ratings downgraded Xilio Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, August 6th. Wall Street Zen cut Xilio Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Xilio Therapeutics presently has a consensus rating of "Sell".

Institutional Trading of Xilio Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in shares of Xilio Therapeutics in the 4th quarter valued at $27,000. Velan Capital Investment Management LP acquired a new position in shares of Xilio Therapeutics in the fourth quarter valued at approximately $109,000. State Street Corp increased its position in shares of Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company's stock worth $119,000 after acquiring an additional 22,500 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company's stock worth $277,000 after acquiring an additional 93,338 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company's stock worth $220,000 after acquiring an additional 139,716 shares during the period. 54.29% of the stock is owned by institutional investors.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company's lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source